Use of endomyocardial biopsy to assess anthracycline-induced cardiotoxicity.
Jones
Robin L
RL
Department of Medical Oncology, Royal Marsden Hospital, London, UK. Robin.jones@icr.ac.uk
Miles
David W
DW
D018943:Anthracyclines / Q000009:adverse effects* / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use; D001706:Biopsy; D009202:Cardiomyopathies / Q000139:chemically induced / Q000473:pathology*; D003630:Daunorubicin / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D004562:Electrocardiography; D006801:Humans; D009206:Myocardium / Q000473:pathology*
D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin; D003630:Daunorubicin